This announcement is made by Peijia Medical Limited (the “Company”, together with its subsidiaries, the “Group”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and product development progress of the Group. The board (the “Board”) of directors (the “Directors”) of the Company is pleased to announce certain unaudited operating statistics of the Group for the year ended December 31, 2024 (the “Reporting Period”), and the comparative figures as set out below. 

 the Group’s continued fast growth in all neurointerventional product lines; and (ii) the Group’s expanded share in the Chinese transcatheter aortic valve replacement (“TAVR”) market. 

 During the Reporting Period, the neurointerventional product lines for hemorrhagic, ischemic and vascular access all achieved remarkable revenue growth, driven by the increased procedure penetration, the Group’s successful bids in the Volume-based Procurements (“VBPs”), as well as its comprehensive product pipeline and effective marketing strategies. The key drivers include:  (i) the successful first-year nationwide launch of DCwire® Micro Guidewire validated by positive user feedback and widespread market adoption;  (ii) the further market penetration of the Group’s existing advantageous products, Syphonet® Stent Retriever and Fastunnel® Delivery Balloon Dilatation Catheter, via differentiated product design and innovative procedure techniques; and  (iii) the sustained adoption of the Group’s coil products under the VBPs, bolstered by reliable product quality and brand recognition. During the Reporting Period, the Group remained dedicated to market education and development, continuously expanding the market share of its first-and second-generation TAVR products, namely TaurusOne® and TaurusElite®. During the Reporting Period, TaurusOne® and TaurusElite® were adopted by over 150 new hospitals, with a total of more than 3,400 units implanted throughout the year. As of December 31, 2024, the Group’s TAVR products had covered nearly 650 hospitals cumulatively.  

 As at the date of this announcement, the Company is still in the process of preparing and finalizing the annual results of the Group for the Reporting Period. The above operating information is preliminary unaudited information that has not been reviewed, confirmed or audited by the auditors of the Company, nor reviewed by the audit committee of the Board, and is provided for investors’ reference only and it shall not be taken as a measure or indication of the Group’s future financial performance. Shareholders and potential investors are advised to read carefully the announcement of the Company in relation to the results of the Group for the Reporting Period, which is expected to be published in March 2025 in accordance with the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.